Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines–Heart Failure (GWTG-HF)

JACC: Heart Failure

Volumn 5, Issue 4, 2017, Pages 305-309

  Luo, Nancy ^a,b   Fonarow, Gregg C ^c   Lippmann, Steven J ^b   Mi, Xiaojuan ^b   Heidenreich, Paul A ^d   Yancy, Clyde W ^e   Greiner, Melissa A ^b   Hammill, Bradley G ^a,b   Hardy, N Chantelle ^b   Turner, Stuart J ^f   Laskey, Warren K ^g   Curtis, Lesley H ^a,b   Hernandez, Adrian F ^a,b   Mentz, Robert J ^a,b   O'Brien, Emily C ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

early adoption; new therapy; sacubitril valsartan

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; MINERALOCORTICOID ANTAGONIST; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; AGE; ANTAGONISTS AND INHIBITORS; CLINICAL PRACTICE; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPRILYSIN; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TETRAZOLES;

EID: 85016561109     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.12.018     Document Type: Article

References (5)

1. 1 McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
2. 2 Institute of Medicine, Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. 2001, National Academy Press, Washington, District of Columbia.
3. 3 Feldman, A.M., Haller, J.A., DeKosky, S.T., Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 315 (2016), 25–26.
4. 4 Fonarow, G.C., Hernandez, A.F., Solomon, S.D., Yancy, C.W., Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol 1 (2016), 714–717.
5. 5 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68 (2016), 1476–1488.